Can Foreign Biotech Companies Own 100% of a Drug Manufacturing Facility in China?

A comprehensive analysis of foreign ownership rules, licensing requirements, and practical considerations for biotech manufacturing in China.

Introduction

One of the most frequently asked questions by foreign biotech companies considering China as a manufacturing base is whether they can own 100% of a drug manufacturing facility. The short answer is yes — since China’s revision of the Foreign Investment Negative List in 2018–2021, foreign companies have been permitted to establish wholly foreign-owned enterprises (WFOEs) for drug manufacturing in most categories. However, the path to full ownership involves navigating a complex web of regulatory requirements, licensing procedures, and operational constraints that go well beyond standard WFOE registration. This article provides a detailed examination of the legal framework, licensing process, and practical considerations for foreign biotech companies seeking 100% ownership of drug manufacturing facilities in China in 2025–2026.

The Legal Framework: Foreign Investment Negative List and Drug Manufacturing

China’s Foreign Investment Negative List, updated most recently in 2024, defines the sectors in which foreign investment is restricted or prohibited. Under the 2024 Negative List (effective from November 2024), the manufacturing of drugs — including chemical drugs, active pharmaceutical ingredients (APIs), biologics, and traditional Chinese medicines — is not listed as a restricted sector. This means foreign investors can establish wholly-owned manufacturing facilities without requiring a Chinese joint venture partner. The key milestones in this liberalization include:

• 2018: The Negative List removed the requirement for Chinese joint venture partners in vaccine manufacturing.
• 2020: Blood product manufacturing restrictions were removed from the Negative List, though practical approvals remain challenging.
• 2021–2024: Ongoing refinements have maintained the open status for drug manufacturing while tightening requirements in other sectors.

It is important to note that while the Negative List permits 100% foreign ownership, certain subcategories of drug manufacturing — particularly narcotic drugs, psychotropic substances, and certain precursor chemicals — are regulated by separate laws and may face additional restrictions regardless of the Negative List provisions.

Establishing the Manufacturing Entity: WFOE Structure

A foreign biotech company establishing a drug manufacturing facility in China will typically do so through one of the following corporate structures:

• Manufacturing WFOE (Wholly Foreign-Owned Enterprise): This is the most common structure for 100% foreign-owned drug manufacturing. The WFOE is registered as a limited liability company under Chinese company law and licensed specifically for drug manufacturing activities.
• Foreign-invested limited liability company (FILLC): For larger operations, some foreign companies choose to establish a FILLC, which offers more flexible governance structures while maintaining 100% foreign ownership.
• Branch office of a foreign company: Less common for manufacturing due to tax implications and operational limitations, but possible in certain special economic zones.

The registration process for a manufacturing WFOE involves approval from the Ministry of Commerce (MOFCOM) or local equivalent, registration with the State Administration for Market Regulation (SAMR), and specific approvals from the NMPA for drug manufacturing activities. The total registration timeline is typically 3 to 6 months for a standard WFOE, but can extend to 6 to 12 months when drug manufacturing licenses are involved.

Drug Manufacturing License: The Critical Permit

Beyond the basic WFOE registration, a biotech manufacturing facility must obtain a Drug Manufacturing License (DML, or “Yao Pin Sheng Chan Xu Ke Zheng”) from the provincial-level NMPA office. This license is the most critical regulatory hurdle for foreign-owned manufacturing facilities. Requirements include:

• Qualified personnel: The facility must employ a legally qualified “Person in Charge” (responsible person), a quality management officer, and a production management officer. These individuals must meet specific educational and experience requirements under the Drug Administration Law.
• GMP-compliant facilities: The manufacturing facility must be designed, constructed, and operated in accordance with China’s Good Manufacturing Practice (GMP) standards, which align closely with PIC/S GMP guidelines.
• Quality management system: A comprehensive quality management system covering raw material control, production processes, in-process testing, finished product release, stability studies, and deviation management.
• Equipment and technology: Appropriate manufacturing equipment, environmental monitoring systems, and for biologics, biosafety containment facilities (BSL-2 or BSL-3 as applicable).
• Product scope definition: The DML specifies the types of drugs the facility is authorized to manufacture — sterile injectables, oral solid dosage forms, APIs, biologics, etc. Foreign companies must define their product scope carefully and seek amendment for any scope changes.

Biologics-Specific Requirements for Foreign-Owned Facilities

Biologic drug manufacturing involves additional regulatory requirements beyond those for chemical drugs:

• Biosafety approvals: Facilities handling genetically modified organisms or pathogenic microorganisms must obtain biosafety approvals from the Ministry of Agriculture and Rural Affairs or the Ministry of Ecology and Environment, depending on the nature of the biologic.
• Cell banking: For cell-based biologics, master cell banks (MCBs) and working cell banks (WCBs) must be established in China or imported under strict quarantine and testing protocols.
• Viral clearance validation: The manufacturing process must include validated viral inactivation and removal steps, with documentation submitted as part of the GMP inspection.
• Cold chain and supply chain: Biologics facilities must have validated cold chain systems for storage and distribution, with temperature mapping and monitoring per Chinese Pharmacopoeia standards.
• Blood product restrictions: Despite the Negative List opening, blood product manufacturing facilities operated by foreign companies face de facto restrictions due to the Blood Donation Law and plasma collection regulations that limit foreign participation in plasma collection stations.

Land and Facility Considerations for Foreign Manufacturers

Foreign-owned manufacturing facilities face several practical considerations regarding land use and facility construction:

• Industrial land use rights: All land in China is state-owned and granted through land use rights. Foreign manufacturing WFOEs can obtain industrial land use rights for 50-year terms. Land purchase or lease requires approval from local land bureaus and may involve competitive bidding processes in high-demand areas.
• Special economic zones and industrial parks: Many foreign biotech companies choose to locate in dedicated bio-pharmaceutical industrial parks such as the Zhangjiang Hi-Tech Park (Shanghai), Zhongguancun Life Science Park (Beijing), Suzhou BioBay, or Guangzhou International Bio Island. These parks offer purpose-built facilities, shared utilities (steam, compressed air, waste treatment), and streamlined approval processes.
• Environmental impact assessment: All drug manufacturing facilities must undergo an environmental impact assessment (EIA) before construction. The EIA process for foreign-owned facilities is the same as for domestic companies, but may face additional scrutiny for facilities handling hazardous materials.
• Construction permits and fire safety: Pharmaceutical construction projects must comply with specific building codes for cleanrooms, hazardous material storage, and fire safety. The approval process for foreign-invested construction projects typically takes 3 to 6 months.

Imported vs. Domestic Manufactured Drugs: Regulatory Implications

One important strategic decision for foreign biotech companies is whether to manufacture drugs in China (domestic manufacturing) or import finished products from overseas. Each approach has distinct regulatory implications:

• Domestic manufacturing (China WFOE): Drugs manufactured at a foreign-owned WFOE facility in China are classified as “domestic drugs” for NMPA registration purposes. This allows the company to use the domestic drug registration pathway (Class 1, 2, 3, or 4 chemical drugs or Class 1 or 2 biologics), which generally has shorter review timelines than the imported drug pathway. The facility must pass NMPA GMP inspection every 3–5 years.
• Imported drugs: Drugs manufactured overseas and imported into China follow a separate registration pathway with potentially longer review times and additional requirements for overseas GMP inspections (which the NMPA increasingly conducts through remote inspection mechanisms). Imported drugs also face supply chain risks including customs clearance delays and quota restrictions for certain controlled substances.
• Hybrid approach: Some foreign companies choose to manufacture bulk drug substances overseas while performing finishing, packaging, and quality control at a China WFOE facility. This hybrid approach can optimize tax treatment and supply chain efficiency while maintaining regulatory advantages.

Tax and Financial Considerations

Foreign-owned drug manufacturing facilities in China benefit from certain tax incentives and face specific financial considerations:

• Preferential income tax rate: High-tech enterprises certified under the High and New Technology Enterprise (HNTE) program pay a reduced corporate income tax rate of 15% (vs. the standard 25%). Many biotech manufacturing WFOEs qualify for HNTE status.
• Research and development super deduction: R&D expenses incurred in China can be deducted at 100% of actual expenditure for tax purposes (200% super deduction effective from 2023).
• VAT policies: Drug manufacturing involves a 13% VAT rate on most products, with certain biologics eligible for simplified VAT calculation at 3%. Export of manufactured drugs may qualify for VAT refund.
• Customs duties on imported equipment: Foreign-invested manufacturing facilities may be eligible for duty-free import of manufacturing equipment under certain conditions, particularly in free trade zones.
• Capital contribution and financing: The WFOE’s registered capital must be commensurate with the investment scale of the manufacturing facility. Foreign companies should plan capital contributions carefully to meet both Chinese regulatory requirements and their own financial planning objectives.

Common Challenges and Risk Mitigation Strategies

Foreign biotech companies pursuing 100% ownership of drug manufacturing facilities in China should be prepared for the following challenges:

• Regulatory complexity: The multi-agency approval process involving SAMR, provincial NMPA, local health authorities, environmental protection bureaus, and fire safety departments can be overwhelming without experienced local consultants.
• IP protection concerns: Manufacturing in China raises concerns about trade secret protection and technology transfer. Companies should implement robust IP protection strategies including patent registration in China, trade secret protection agreements with employees, and careful management of manufacturing know-how.
• Supply chain dependency: Raw materials, excipients, and packaging materials for pharmaceutical manufacturing in China may have limited domestic alternatives, creating supply chain dependency. Foreign companies should conduct thorough supplier qualification and maintain buffer stocks.
• Talent acquisition: Finding qualified personnel for GMP-compliant manufacturing operations — particularly experienced quality assurance managers and regulatory affairs professionals — is competitive in China’s major biotech hubs.
• Inspection readiness: NMPA GMP inspections for new manufacturing facilities are thorough, typically lasting 3–5 days and covering all aspects of quality management. Foreign companies should conduct readiness audits before the formal inspection.

Conclusion

Yes, foreign biotech companies can own 100% of a drug manufacturing facility in China under current regulations. The 2018–2024 revisions to the Foreign Investment Negative List have opened drug manufacturing to wholly foreign-owned enterprises, and this policy framework is expected to remain stable. However, full ownership is just the starting point — establishing and operating a drug manufacturing facility in China requires navigating a multi-layered regulatory system including WFOE registration, Drug Manufacturing License application, GMP certification, environmental approvals, and biosafety permits. For foreign biotech companies willing to invest in understanding and complying with these requirements, China offers a world-class manufacturing ecosystem with competitive costs, a skilled workforce, and integration into one of the world’s fastest-growing pharmaceutical markets.

This article is for informational purposes only and does not constitute legal or regulatory advice. Foreign investment regulations, tax policies, and licensing requirements are subject to change. Foreign companies should consult qualified legal and regulatory professionals for advice specific to their manufacturing plans and product portfolio.